Evidence map›Paper›PMID 42547607›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Clinical impact of

Sanxing Feng, Yizhao Xie, Cheng Liu, Yumeng Li, Jincheng Luo, Xichun Hu, Shaoli Song, Biyun Wang, Zhongyi Yang

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sanxing Feng *Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yizhao Xie *Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Cheng Liu *Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yumeng LiDepartment of Oncology, Huadong Hospital Affiliated to Fudan University, Shanghai, 200040, China.
Jincheng LuoDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xichun HuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. huxichun2017@163.com.
Shaoli SongDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. shaoli-song@163.com.
Biyun WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. wangbiyun0107@hotmail.com.
Zhongyi YangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. yangzhongyi21@163.com.ORCID http://orcid.org/0000-0001-6195-9942

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeReceptor discordance between primary and metastatic breast cancer is increasingly recognized and may influence treatment decisions in metastatic breast cancer (MBC) patients.

methodsThis retrospective study screened 1330 patients with metastatic breast cancer who underwent

results

conclusionER-positive conversion assessed by

Indexed as

18F-FES PET/CTEndocrine therapyER-positive conversionEstrogen receptorMetastatic breast cancerReceptor discordance

Identifiers

PMID42547607

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.